BioPharma Dive November 23, 2021
Dive Brief:
- AstraZeneca on Tuesday officially opened its new $1.3 billion corporate headquarters and research hub in Cambridge, U.K., an initiative that began eight years ago as the British drugmaker sought to revitalize its R&D pipeline by forging new ties with academic researchers and small biotech companies.
- The location will be AstraZeneca’s second-biggest by headcount, the base for 3,300 employees, and at the center of the largest biomedical cluster in Europe. AstraZeneca said the site will house the advanced technology necessary to “foster the discovery and development of next generation therapeutics, including nucleotide-based, gene-editing and cell therapies.”
- Opening the building, which comes years later than originally planned, completes a process of consolidating most of its British operations under a...
Today's Sponsors
Today's Sponsor